Methocarbamol does not show potential for interaction with CYP enzymes, and no porphyrinogenic effects have been identified.

Carbamatic acid ester

Methocarbamol is a centrally acting muscle relaxant used in the treatment of musculoskeletal pain. It is administered orally or intravenously, and has a half-life of about 2 hours (SPC).

Methocarbamol is metabolised in the liver, but data on the involvement of CYP enzymes are lacking (SPC, DrugBank). Methocarbamol did not show any potential for significant interactions with CYP3A4, CYP2C8, CYP2B6 or CYP2D6 in an in vitro study (Moody 2018).